Aceragen | L'Utile Ante Imposte



L'Utile Ante Imposte Cambiamento Data
Abbott USD 2.36B 178M 2025-12
Agenus USD -274.14M 80.46M 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
Amgen USD 3.92B 2.35B 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Cipla INR 11.69B 6.85B 2025-12
Clal Biotechnology ILS 86.82M 17.9M 2022-12
Compugen USD -6.94M 421K 2025-09
CSL USD 1.4B 1.14B 2025-06
Eli Lilly USD 7.23B 456M 2025-09
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Grifols EUR 66.98M 19.92M 2024-06
Merck USD 6.74B 22M 2025-09
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Pfizer USD 3.33B 290M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -194.05M 347.69M 2025-09
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
X T L Biopharmaceuticals USD -385K 168K 2024-12


Aceragen L'Utile Ante Imposte - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.